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Objective: To determine the frequency of use of pharmacotherapy with aspirin, beta blocker, 
statin, and angiotensin-converting enzyme (ACE) inhibitor in patients with stable coronary heart 
disease (CHD) among physicians at different levels of health care in Rajasthan state, India.
Methods: Physicians practicing at tertiary hospitals and clinics at tertiary, secondary and 
primary levels were contacted. Prescriptions of CHD patients were audited and descriptive 
statistics reported.
Results: We evaluated 2,993 prescriptions (tertiary hospital discharge 711, tertiary 688, 
secondary 1,306, and primary 288). Use of aspirin was in 2,713 (91%) of prescriptions, beta 
blockers 2,057 (69%), ACE inhibitors or angiotensin receptor blockers (ARBs) 2,471 (82%), 
and statins 2,059 (69%). Any one of these drugs was prescribed in 2,991 (100%), any two in 
2,880 (96%), any three in 1,740 (58%), and all four in 1,062 (35.5%) (P  0.001). As compared 
to tertiary hospital, prescriptions at tertiary, secondary, and primary levels were lower: aspirin 
(96% vs 95%, 91%, 67%), beta blockers (80% vs 62%, 66%, 70%), statins (87% vs 82%, 62%, 
21%): two drugs (98% vs 96%, 98%, 85%), three drugs (75% vs 58%, 55%, 28%), or four drugs 
(54% vs 44%, 28%, 7%) (P  0.01). Use of ACE inhibitors/ARBs was similar while nitrates 
(43% vs 23%, 43%, 70%), dihydropyridine calcium channel blockers (12% vs 15%, 30%, 47%), 
and multivitamins (6% vs 26%, 37%, 47%) use was more in secondary and primary care.
Conclusions: There is suboptimal use of various evidence-based drugs (aspirin, beta blockers, 
ACE inhibitors, and statins) for secondary prevention of CHD in India.
Keywords: statins, coronary heart disease, aspirin, beta blockers, angiotensin-converting 
enzyme inhibitor
Background
Guidelines based on evidence from randomized controlled trails recommend that 
aspirin, beta-adrenergic blockers, angiotensin-converting enzyme (ACE) inhibitors, 
and hydroxyl methyl glutarate coenzyme A reductase inhibitors (statins) be used in all 
patients with symptomatic chronic stable angina or asymptomatic survivors of acute 
myocardial infarction and following percutaneous coronary intervention or coronary 
bypass surgery for secondary prevention of myocardial infarction, stroke and death.1–4 
It has been hypothesized that if used collectively these agents could reduce long term 
risk of cardiovascular events and mortality by as much as 75%.5 However the actual 
impact depends on the extent to which they are used in practice.6–8
The EUROASPIRE studies of pharmacological practice patterns in stable coro-
nary heart disease (CHD) patients evaluated secondary prevention in nine countries 
in Europe.9–11 In the first study a very low use of ACE inhibitors and lipid-lowering 
Vascular Health and Risk Management 2009:51008
Sharma et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
drugs and suboptimal use of aspirin and beta-blockers was 
observed.9 The EUROASPIRE-2 study reported increasing, 
though suboptimal, use of antiplatelet agents, ACE inhibitors 
and beta-blockers and a large increase in statin use.10 The 
EUROASPIRE-3 study has reported unchanged use for 
prescriptions for beta-blockers, ACE inhibitors or angiotensin 
receptor blockers (ARBs) and statins.11 The North American 
National Registry of Myocardial Infarction (NRMI) reported 
a low use of such therapies in 1990s (NRMI-1) with a 
subsequent increase in follow-up studies (NRMI-2 and 
NRMI-3).12 On the other hand, the World Health Organization 
(WHO) PREMISE study in eight low and middle income 
countries in Asia, Africa, Europe, and South America 
reported low and variable use in patients with established 
cardiovascular diseases including survivors of coronary 
event or stroke.13 Use of all types of evidence-based medical 
therapies (aspirin, beta-blockers, ACE inhibitors, statins) was 
low in this and other studies in India.13–16 On the other hand, 
a large acute coronary syndrome registry reported high use 
of evidence-based therapies in secondary and tertiary care 
hospitals.17 Attrition of such therapies as these patients shift 
to chronic care is not known.
Presently, there is no significant information on the 
prescribing pattern of recommended drugs for secondary 
prevention of CHD at various levels of health care (primary, 
secondary, tertiary, or tertiary hospital-based) in India. 
Frequency of use of multiple nonevidence-based therapies in 
stable patients with CHD has also not been well documented. 
We analyzed use of evidence-based medicines for secondary 
prevention of CHD among patients with symptomatic chronic 
stable angina or survivors of acute coronary syndromes in 
settings of rural and urban primary, secondary, tertiary care, 
and tertiary care hospital discharge levels.
Methods
The study was approved by the local institutional ethics 
committee. A proforma was prepared that included demo-
graphic details of patients, diagnoses, and drug prescriptions. 
Data on demographic and personal detail of physicians were 
also collected. Physicians were classified as primary care 
physicians who had basic qualifications and were working 
in rural or urban clinics and dispensaries; secondary level 
physicians were having a postgraduate qualification in internal 
medicine and practising independently or in government 
clinics, primary health centers or secondary level govern-
ment or private hospitals; and tertiary level physicians were 
those with subspecialty qualification in cardiology, cardiac 
surgery, endocrinology, etc, and tertiary level hospitals with 
cardiac invasive and surgical management. The trade names 
of drugs were deciphered and classified into pharmaco-
logical groups that included aspirin, clopidogrel or other 
antiplatelet agents, beta-blockers, ACE inhibitors or ARBs, 
statins, other lipid-lowering medicines such as fenofibrate, 
short- and long-acting nitrates, dihydropyridine or nondi-
hydropyridine calcium channel blockers (CCBs), potassium 
channel openers (eg, nicorandil), metabolic modulators 
(eg, trimetazidine), antioxidants, multivitamins, diabetic 
medications, and other medications.
The study was performed at all large districts of 
Rajasthan state over a period of 15 months from September 
2007 to December 2008. Rajasthan is the largest state in 
India and is at the median of the national human develop-
ment index and other social indices. Consent from the 
physicians prescribing at primary, secondary, and tertiary 
sites was obtained and the prescriptions were studied during 
a single day at the local pharmacy. This was to minimize 
bias and negate the influence of changing the prescribing 
habit once awareness of monitoring was apparent. We could 
evaluate prescriptions of 43 general practitioners or primary 
care physicians, 61 internists or secondary care physicians, 
eight diabetologists, and 18 cardiologists in tertiary care 
and tertiary care hospital discharge prescriptions from 
three tertiary care hospitals with 14 cardiologists. The 
age-distribution of these physicians is shown in Table 1. 
The primary and secondary care physicians are older than 
those working at tertiary care centers and hospitals. The 
state has more than 20,000 registered qualified medical 
practitioners at primary, secondary, and tertiary care levels. 
Details of specialization are not available at the local 
medical council.
Table 1 Age of physicians at different health care levels
Age-groups Tertiary care 
hospital (n = 14)
Tertiary care  
physicians (n = 26)
Secondary care 
physicians (n = 61)
Primary care  
physicians (n = 43)
30–45 6 (42.9) 11 (42.4) 21 (34.5) 13 (30.2)
46–60 6 (42.9) 13 (50.0) 25 (40.9) 17 (39.5)
60+ 2 (14.2) 2 (7.5) 15 (24.5) 13 (30.2)
Note: numbers in parentheses are percentages.
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Interviews were organized with the patients after their 
consent and only those patients who had an established 
diagnosis of CHD are included. Approximately 60% of 
eligible patients (3,013/5,000) recruited from the outpatient 
clinics of primary, secondary, and tertiary health care 
facilities and tertiary care hospitals agreed to provide details 
of prescriptions. Twenty prescriptions were illegible and 
2,993 were included in the prescription audit. The medicines 
obtained from these prescriptions were deciphered and trade 
names translated into pharmacological molecules.
Statistical analyses
All the data were analyzed centrally using SPSS software 
(v. 10.0; SPSS Inc., Chicago, IL). Descriptive data are 
reported as numbers and percentages. The significance of 
intergroup differences was analyzed using chi-squared test. 
Trends in prescribing patterns at different levels of care 
were assessed using Mantel–Haenszel chi-squared test for 
trend. Odds ratio (OR) was used to assess difference in use 
of various drugs at tertiary, secondary, and primary level 
of care compared with tertiary level hospital discharge 
(OR, 1.0) and were calculated using logistic regression 
analyses. P values  0.05 were considered significant.
Results
We evaluated 2,993 persons and their prescriptions (tertiary 
level hospital discharge, 711; tertiary level specialists, 688; 
secondary care physicians, 1,306; primary care physicians, 288). 
In a recent national study of health care-seeking behavior for 
chronic diseases, it was reported that 21.5% patients visited 
primary level care, 52.4% utilized secondary level care, and 
26.1% accessed tertiary level care.18 This is similar to the 
present study enrollment and shows that more than 50% of 
patients with chronic diseases access secondary level care 
for their treatment (Table 2). The mean age of patients in 
the study was 60.5 ± 14.1 years, more than 50% of patients 
were aged 45–65 years, and 70.6% were men. The median 
time after the acute coronary event or diagnosis of stable 
CHD was 30 months (interquartile range, 18–54 months). 
The largest group of patients was with stable angina pectoris 
(65%) followed by survivors of unstable angina or acute 
myocardial infarction.
Use of various drugs classes is shown in Table 3. Aspirin 
was prescribed in 2,713 (90.6%), beta blockers in 2,057 
(68.7%), ACE inhibitors or ARBs in 2,471 (82.5%), statins in 
2,059 (68.8%), other lipid-modifying drugs in 405 (13.5%), 
nitrates in 1,228 (41.1%), dihydropyridine CCBs in 
716 (23.9%), nondihydropyridine CCBs in 423 (14.1%), 
potassium channel openers in 481 (16.1%), myocardial 
metabolic modulators in 424 (14.2%), antioxidants in 
257 (8.6%), vitamins in 839 (28.0%), and diabetes medica-
tions in 1,163 (39.3%). Any one of the four evidence-based 
drugs (aspirin, beta-blockers, ACE inhibitors/ARBs, and 
statins) was prescribed in 2,991 (99.9%) subjects, any two 
in 2880 (96.2%), any three in 1,740 (58.1%), and all four 
in 1062 (35.5%) (χ2 for trend, P  0.001). As compared to 
tertiary care hospital discharge, the respective prescriptions 
at tertiary care, secondary care, and primary level care 
were significantly lower for aspirin (96.1% vs 94.6%, 
90.8%, 67.0%, respectively), beta blockers (79.6% vs 
62.1%, 66.1%, 69.8%, respectively), statins (86.9% vs 
82.4%, 62.3%, 20.8%, respectively) as well as for two drug 
(97.7% vs 96.3%, 97.5%, 85.1%, respectively), three 
drug (75.4% vs 58.4%, 55.3%, 27.8%, respectively), or four 
drug (53.7% vs 43.5%, 27.7%, 6.6%, respectively) combi-
nations (χ2 for trend, P  0.01) (Figure 1). Use of nitrates 
(43.4% vs 23.1%, 43.0%, 69.8%, respectively), dihydro-
pyridine calcium channel blockers (12.3% vs 15.4%, 29.6%, 
47.2%, respectively), antioxidants (0.8% vs 12.6%, 11.3%, 
5.9%, respectively) and multivitamins (6.3% vs 25.6%, 
37.1%, 46.5%, respectively) was greater in primary and 
secondary care. Use of ACE inhibitors/ARBs was more 
common in patients at tertiary and secondary care levels 
(Table 3).
Univariate statistics revealed that as compared to tertiary 
care hospital discharge prescriptions there was a gradual attri-
tion of prescriptions of aspirin, beta blockers, ACE inhibitors/
ARBs and statins in chronic tertiary care, secondary care, 
Table 2 Utilization of health care as outpatient services for chronic diseases in india and the present study
Chronic care foundation 
of India national study18  
(n = 1,856)
Present study subjects  
excluding tertiary hospital 
discharge (n = 2,282)
Primary care 21.5% 12.6%
Secondary care 52.4% 57.2%
Tertiary care 26.1% 30.1%
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and primary care, respectively (χ2 for trend, P  0.001) 
(Table 3). Use of combinations of evidence-based therapies 
(aspirin, beta-blockers, ACE inhibitors/ARBs, and statins) 
was also significantly lower at primary and secondary level 
of care. As compared with tertiary level hospitals, the OR 
(95% confidence intervals [CI]) for use of two, three, and 
four drug combinations at primary care was OR, 0.13 (95% 
CI: 0.07–0.24), OR, 0.13 (95% CI: 0.09–0.17) and OR, 
0.06 (95% CI: 0.04–0.01) and at secondary care was OR, 
1.01 (95% CI: 0.55–1.88), OR, 0.40 (95% CI: 0.33–0.49), 
and OR, 0.33 (95% CI: 0.27–0.40), respectively (Table 4).
Discussion
This study shows that in the Rajasthan state of India, the 
use of evidence-based secondary prevention cardiovascular 
therapies is low in chronic management of CHD at primary 
and secondary care levels. The use appears adequate at tertiary 
level hospital discharge. But here also is lower than recom-
mended by the American College of Cardiology/American 
Heart Association guidelines1 and British quality outcomes 
framework.19 High use of nonevidence-based dihydropyridine 
CCBs, nitrates, antioxidants, and multivitamins in primary 
and secondary care is also observed.
There is robust scientific evidence for recommending the 
use of aspirin, lipid-lowering agents especially statins, beta-
adrenergic blockers, and ACE inhibitors for the secondary 
prevention of cardiovascular disease.1–4 Multiple large studies 
as well as meta-analyses have reported decreased clinical 
events and mortality and there is incremental benefit with 
their use.5 Historically mortality in chronic cardiovascular 
diseases range from 8%–15% per annum.20 This mortality can 
be decreased by currently available evidence-based therapies 
and it has been determined that incremental use of aspirin, beta 
blockers, statins, and ACE inhibitors can reduce the two-year 
cardiovascular mortality from 8% to 2.3%.5 Multiple national 
and international guidelines recommend that for secondary 
prevention aspirin, beta-blockers and statins be used in all 
the patients and ACE inhibitors should be used in those with 
left ventricular dysfunction.21 However, after publication 
of Heart Outcomes Prevention Evaluation (HOPE) study21 
there is a strong evidence of adding ACE inhibitors to other 
drugs and ACCF/AHA guidelines have been since modified.1 
Use of ARBs instead of ACE inhibitors as primary drugs is 
controversial and is not recommended.23
In the present study use of all the four drug classes 
(aspirin, beta blockers, ACE inhibitors/ARB and statins 
was high at discharge from tertiary care hospitals included 
in the study. These findings are similar to studies from 
North America (NRMI),24 western Europe (GRACE),25 
and the Indian CREATE registry.17 In chronic care, on the 
other hand, the use of various evidence-based therapies 
rapidly decline with time.7,8 Aspirin use in the present study 
in combined groups at tertiary, secondary, and primary 
care level is in 2030 of 2,282 patients (88.9%) which is 
Table 3 Frequency of use of various drug classes at different prescriber levels
Drug group Total  
(n = 2,993)
Tertiary care 
hospital  
(n = 711)
Tertiary care 
level physicians 
(n = 688)
Secondary care 
level physicians 
(n = 1,306)
Primary 
care level 
(n = 288)
χ2 square for 
trend (P value)
Aspirin 2,713 (90.6) 683 (96.1) 651 (94.6) 1,186 (90.8) 193 (67.0) 101.41 (0.001)
Beta blockers 2,057 (68.7) 566 (79.6) 427 (62.0) 863 (66.1) 201 (69.8) 8.08 (0.004)
Ace inhibitors/ARBs 2,471 (82.5) 544 (76.5) 607 (88.2) 1,112 (85.1) 208 (72.2) 0.005 (0.946)
Statins 2,059 (68.8) 618 (86.9) 567 (82.4) 814 (62.3) 60 (20.8) 170.77 (0.001)
Other anticholestrol drugs 405 (13.5) 142 (20.0) 102 (14.8) 150 (11.5) 11 (3.8) 28.35 (0.001)
nitrates 1,228 (41.1) 308 (43.4) 158 (23.1) 561 (43.0) 201 (69.8) 31.91 (0.001)
Dihydropyridine ccB 716 (23.9) 87 (12.3) 106 (15.4) 387 (29.6) 136 (47.2) 172.29 (0.001)
nondihydropyridine ccB 423 (14.1) 30 (4.2) 110 (16.0) 250 (19.1) 33 (11.5) 23.25 (0.001)
Potassium channel openers 481 (16.1) 16 (2.3) 139 (20.0) 291 (22.3) 35 (12.2) 15.86 (0.001)
Metabolic modulators 424 (14.2) 13 (1.8) 177 (25.7) 222 (17.0) 12 (4.2) 5.42 (0.02)
Antioxidants 257 (8.6) 6 (0.8) 87 (12.6) 147 (11.3) 17 (5.9) 12.45 (0.001)
B-complex or multivitamins 839 (28.0) 45 (6.3) 176 (25.6) 484 (37.1) 134 (46.5) 262.24 (0.001)
Other medications 1,861 (62.2) 443 (62.1) 441 (64.1) 811 (62.1) 166 (57.6) 1.32 (0.251)
Diabetes medications 1,163 (39.1) 133 (19.0) 324 (47.2) 602 (46.2) 104 (36.2) 10.74 (0.001)
Abbreviations: Ace, angiotensin-converting enzyme;  ARB, angiotensin receptor blockers; ccB, calcium channel blockers.
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similar to the EUROPASPIRE studies9,10 and Indian arm of 
WHO-PREMISE.13 Beta blockers were used in 1,491 (65.3%), 
ACE inhibitors/ARBs in 1,927 (84.4%), and statins in 1,441 
(63.1%). This is significantly greater than the WHO-PREM-
ISE study. The use of beta-blockers and statins is similar 
to the EUROASPIRE study, but that of ACE inhibitors is 
greater. The high use of ACE inhibitors/ARBs was observed 
in all physician groups. Physician prescribing behavior is 
influenced by multiple factors26 and it is likely that aggres-
sive marketing of ARBs have influenced the practice patterns 
while use of other drugs that are older and were not marketed 
aggressively is lower.
One of the major limitations of the study is that it has been 
performed in a single state of India and the results cannot 
be transposed to the whole country given the considerable 
social, cultural, and medical service-related heterogeneity of 
India. On the other hand, in terms of social and economic 
developmental indices, Rajasthan is at the median level27 
and the results obtained from various classes of physicians 
could be similar to the entire nation. Secondly, the study 
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Figure 1 Percent use of evidence-based therapies at different levels of care. A) Use of aspirin is low in primary care, beta-blocker use is low in tertiary and secondary 
care clinics, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (Ace/ARB) use is low in tertiary care and primary care while statin use is 
low is secondary and primary care. B) Use of multiple therapies shows a significantly declining trends from tertiary care hospital discharge to primary care level 
(P for trend  0.01).
Vascular Health and Risk Management 2009:51012
Sharma et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
was confined to major cities and district headquarters of the 
state and therefore the situation regarding CHD secondary 
prevention therapies in general population and among 
patients who attend primary care facilities in rural and 
semiurban locations was not available. The situation in these 
locations is likely to be worse than in our sample as has been 
reported for other disease conditions.27 Thirdly, we obtained 
more prescriptions from physicians at secondary (internists) 
and tertiary (cardiologists, specialists) levels as compared to 
those at primary level and this may have skewed the overall 
prescription pattern. However, it has been reported in India 
that most of the patients with established CHD either obtain 
treatment directly from the specialists or the internists, and 
primary level physicians are not in the cardiovascular care 
loop.18 Fourthly, this is a retrospective prescription audit 
study rather than a prospective study. But only studies 
of this kind provide the real-life data and this is a study 
strength. Similar strategies are used in the EUROASPIRE 
studies9–11 and the EuroHeart surveys.28 Fifthly, we have no 
data of the CHD subtype (acute ST elevation infarction, acute 
non-Q infarction, unstable angina, chronic stable angina or 
congestive heart failure), and associated cardiovascular risk 
factors such as smoking, hypertension, hypercholesterolemia 
and diabetes. All these can modify prescribing patterns. 
Sixthly, for statistical analyses we did not control for type 
of disease, disease severity, cardiovascular risk factors, 
other comorbidities, physician age, or time in practice. All 
these can influence prescription and prescribing habits. In 
the present study, it is observed that physicians at primary 
and secondary care levels are older than at tertiary care level 
(Table 1). Older physicians are known to be less compliant 
with recent developments.6,7 The study shows that this could 
be a factor that influences prescriptions. And finally, drug 
treatment is not the only effective method of secondary 
prevention.1 We did not inquire regarding dietary advice, 
smoking cessation, weight reduction, physical exercise, 
and other nonpharmacological preventive interventions. 
The study strengths include a large number of prescriptions 
analyzed that are more than any contemporary studies from 
developing countries, a large and heterogeneous geographical 
distribution of the study locales, short time awareness of the 
prescribing physicians to the study with unlikely change in 
prescribing habits, and a single person deciphering the pre-
scriptions. Despite multiple limitations, the study provides a 
useful insight into current practice with regard to secondary 
prevention.
The study results show appropriate use of evidence-based 
therapies at tertiary care level and low use in primary and 
secondary care shows a slow transmission of knowledge of 
current evidence-based strategies in secondary prevention 
of CHD to these physicians. The structure and performance 
of health systems in this country might be party responsible for 
this difference.29 Other reasons for the treatment gaps observed 
in this study could be at the level of health systems, health 
care providers, and patients (Table 5). We have not studied 
these determinants. Bearing in mind that in this study about 
three quarters of patients accessed primary and secondary 
health care facilities for obtaining treatment, these physicians 
need to be targeted in continuing medical education programs 
related to secondary prevention and should be provided with 
suitable incentives to engage in prevention.
In conclusion, despite availability of low-cost and effective 
pharmacological interventions,30 there are significant gaps in 
secondary prevention of CHD in primary and secondary care 
in India. There is a need to increase access to preventative drug 
therapy and to improve the quality of health provider-related 
care. Health system capacity needs to be enhanced through 
development of effective national drug policies, rational and 
evidence-based selection of medicines for inclusion in national 
drug lists, affordable price for pharmaceuticals, and sustain-
able financing and supply systems.6 Policies are also required 
to strengthen infrastructure of health care facilities, particularly 
at the primary and secondary health care levels, and to provide 
continuing medical education to health care providers. To 
ensure sustainability of these measures, they need to be sup-
ported with complementary population-wide strategies that 
promote healthy lifestyles and educate individuals regarding 
the importance of secondary prevention.31 Finally, effective 
Table 4 Odds ratios (95% confidence intervals) for use of evidence-based therapies at different levels of healthcare compared with 
tertiary hospital discharge (odds ratio = 1.0)
Tertiary care Secondary care Primary care
Any two drugs 0.61 (0.32–1.15) 1.01 (0.55–1.88) 0.13 (0.07–0.24)
Any three drugs 0.46 (0.37–0.58) 0.40 (0.33–0.49) 0.13 (0.09–0.17)
All four drugs 0.66 (0.54–0.82) 0.33 (0.27–0.40) 0.06 (0.04–0.10)
Notes: Therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; aspirin or other antiplatelets; beta-blockers; or statins.
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information systems are crucial for monitoring the performance 
of secondary prevention programs. More urgently Indian 
physicians in primary and secondary care need to increase 
the use of widely available secondary preventive measures 
recommended by guidelines. The mandatory use of aspirin, 
statins, beta-blockers, and ACE inhibitors in all patients are 
necessary to reduce the increasing mortality from chronic 
CHD in India.
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